Tumor killing effects of enterotoxins, superantigens, and related compounds
US6692746B1 · kind B1 · utility
Inventors
Key dates
| Filing date | Nov 8, 2000 |
| Grant date | Feb 17, 2004 |
| Priority date | — |
| Expiry date | Jul 27, 2021 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2510/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Superantigens, including Staphylococcal enterotoxins streptococcal pyrogenic exotoxins (SpE's), biologically active fragments and homologues thereof and fission proteins of the native superantigens, homologues and fragments, are useful agents for killing tumor cells, enhancing antitumor immunity and for treating tumors in a tumor-bearing subject. In particular, a subject having a tumor is treated with a tumoricidally effective amount of a superantigen, such as a SE or SpE, or a biologically active homologue thereof, fusion protein thereof or a fusion protein of the homologue. These agents stimulate T cells, leading to increased antitumor immunity and killing of tumor cells.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.